Wednesday, September 25, 2019

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers


Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://ibn.fm/Ljt7D). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . . ChrgD+ has been available in a limited number of retail stores throughout the Western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life  without having to travel. Limited-time promotional offers and product updates are also available through the site.”

To view the full article, visit http://ibn.fm/8mNmZ

About Lexaria Bioscience Corp.

Lexaria is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html